ResMed - Upcoming Key Date, page-2

Price action hovering on the top half of the bollinger band since the last update 3rd Qtr in May. Seems to be good confidence in this stock.

Last results in the 3rd Qtr were:

• Revenue up 12% to $662 million, up 15% on constant currency basis
• Gross margin up 1% to 59.2%
• Net profit $105.4m, compared to $110.1m
• Adjusted earnings per share of US89 cents, down 3%
• GAAP earnings per share of US73 cents, down 4%
• Quarterly dividend of US37 cents
• Software-as-a-service (SaaS) revenue up 101% thanks to Brightree growth and Matrix Care acquisition
• For 9 months ending Mar 31 2019 Non-GAAP EPS of $2.69 versus $2.58 in pcp

What are everyone's expectations in terms of meeting the target? Is there any guidance out here from analysts of what the expectations are on earnings?

My guesstimate:
Revenue increase of say double digit percentage wise 10-15% to ~$650-$710m revenue in 4th Qtr?

1st Qtr 2019 Revenue increase 12% $588.3m; up 13% on constant currency basis

2nd Qtr 2019 Revenue increase 8% $651.1m; up 9% on constant currency basis

3rd Qtr 2019 Revenue increase 12% $662.0m; up 15% on constant currency basis

4th Qtr 2019 Revenue ???

Currently sitting at $1,901.4m

If target 12% growth on 2018 fiscal year would be $2,340.2 x 1.12 = $2,621.024m target for 2019 fiscal year

$2,621.024m - $1,901.4 = $719.624m for 4th Qtr which would be an increase of 15% based on the previous year Qtr.

If target 10% growth on 2018 fiscal year would be $2,340.2 x 1.10 = $2,574.22m target for 2019 fiscal year

$2,574.22m - $1,901.4 = $672.82m for 4th Qtr which would be an increase of 7.89% based on the previous year Qtr.

Looking on https://seekingalpha.com/symbol/RMD/income-statement , they have a forecast trailing twelve months (TTM) of $2,530.0m.
Taking this figure $2,530m - $1,901.4 = $628.6m for 4th Qtr which would be an increase of 0.8% based on the previous year Qtr.
This appears to be a bit low.

1st Qtr 2018 Revenue increase 13% $523.7m; up 11% on constant currency basis

2nd Qtr 2018 Revenue increase 13% $601.3m; up 11% on constant currency basis

3rd Qtr 2018 Revenue increase 15% $591.6m; up 10% on a constant currency basis

4th Qtr 2018 Revenue increase 12% $623.6; up 10% on a constant currency basis

Total 2018 fiscal year revenue $2,340.2m

- - -

https://www.macrotrends.net/stocks/charts/RMD/resmed/revenue

• ResMed revenue for the quarter ending March 31, 2019 was$0.662B, a11.93% increaseyear-over-year.
• ResMed revenue for the twelve months ending March 31, 2019 was$2.525B, a11.08% increaseyear-over-year.
• ResMed annual revenue for 2018 was$2.34B, a13.23% increasefrom 2017.
• ResMed annual revenue for 2017 was$2.067B, a12.4% increasefrom 2016.
• ResMed annual revenue for 2016 was$1.839B, a9.52% increasefrom 2015.